Log In
BCIQ
Print this Print this
 

Mircera, biosimilar epoetin beta, methoxy polyethylene glycol-epoetin beta (R744)

Also known as: formerly Continuous Erythropoiesis Receptor Activator (CERA)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSingle methoxy-polyethylene glycol (PEG) polymer bound to an erythropoietin (EPO) molecule
Molecular Target Erythropoietin (EPO) receptor
Mechanism of ActionErythropoietin (EPO) receptor agonist; Biosimilar
Therapeutic ModalityBiologic
Latest Stage of DevelopmentMarketed
Standard IndicationAnemia
Indication DetailsTreat anemia; Treat anemia in cancer patients; Treat anemia in chronic kidney disease (CKD) patients both on and off dialysis; Treat anemia in chronic kidney disease (CKD) patients not on dialysis; Treat anemia in chronic kidney disease (CKD) patients on dialysis; Treat anemia in dialysis patients; Treat chemotherapy-induced anemia (CIA); Treat renal anemia
Regulatory Designation
PartnerChugai Pharmaceutical Co. Ltd.;
Galenica Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/28/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today